⌕
Intellia Therapeutics · NTLA · Nasdaq
Tenet 41 · Weak
Compare
$9.78−0.81%At closeTenet 41 · Weak
$9.78−0.08 (−0.81%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Intellia Therapeutics (NTLA) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is NTLA's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 12, 2026 · 19:18 ET
Intellia Therapeutics, Inc. (NTLA) Discusses Lonvo-z Clinical Data and Commercial Launch Preparations in HAE Transcript

Intellia Therapeutics, Inc. ( NTLA ) Discusses Lonvo-z Clinical Data and Commercial Launch Preparations in HAE November 12, 2026 10:00 AM EST Company Participants Jason Fredette - Vice President of Investor Relations & C…

NTLA −0.8% todayRead at source ↗
● MarketBeatNov 12, 2026 · 16:15 ET
Intellia Therapeutics' One-Time HAE Therapy Cuts Attacks 87% in Trial as FDA Decision Nears

Intellia Therapeutics NASDAQ: NTLA presented additional clinical data and outlined launch plans for lonvo-z, its investigational one-time gene-editing treatment for hereditary angioedema, as the company awaits a U.S. reg…

NTLA −0.8% todayRead at source ↗
● GlobeNewsWireNov 12, 2026 · 10:00 ETCOMPANY'S OWN WORDS
Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026

CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core techno…

NTLA −0.8% todayRead at source ↗
● GlobeNewsWireNov 10, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Intellia Therapeutics to Present at Jefferies Global Healthcare Conference in London

CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core techno…

NTLA −0.8% todayRead at source ↗
● GlobeNewsWireNov 6, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core techno…

NTLA −0.8% todayRead at source ↗
● Seeking AlphaNov 6, 2026 · 15:24 ETEARNINGS EXPECTED BY JAN 22
Intellia: Quiet Q3 Earnings As All Eyes Turn To March 2027 Approval Decision

Intellia Therapeutics approaches a pivotal FDA decision in March 2027 for lonvo-z, potentially the first in vivo CRISPR therapy for hereditary angioedema. Lonvo-z's Phase 3 data showed ~87% attack reduction and a clean s…

NTLA −0.8% todayRead at source ↗
● Zacks Investment ResearchNov 6, 2026 · 14:26 ETEARNINGS EXPECTED BY JAN 22
Intellia's Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus

NTLA's Q3 loss deepens, while progress on its lonvo-z & nex-z clinical programs & a $400 million loan facility strengthen its pipeline & financial flexibility.…

NTLA −0.8% todayRead at source ↗
● Zacks Investment ResearchNov 5, 2026 · 10:37 ETEARNINGS EXPECTED BY JAN 22
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $0.92 per share a year ago.…

NTLA −0.8% todayRead at source ↗
● GlobeNewsWireNov 5, 2026 · 08:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY JAN 22
Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates

On track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date New lonvo-z patient perspectives and Phase 1/2 durability data to be included in investor webcast and multiple presentatio…

NTLA −0.8% todayRead at source ↗
● GlobeNewsWireNov 4, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)

CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core techno…

NTLA −0.8% todayRead at source ↗
● GlobeNewsWireNov 3, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations

Presentation at AHA on Nov. 9 to highlight cardiac outcomes following a single dose of nex-z in patients with ATTRv-PN with mixed phenotype from the Phase 1 clinical trial Presentation at ISA on Nov. 18 to include up to …

NTLA −0.8% todayRead at source ↗
● GlobeNewsWireOct 29, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026

CAMBRIDGE, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core techno…

NTLA −0.8% todayRead at source ↗
● GlobeNewsWireOct 28, 2026 · 16:15 ETCOMPANY'S OWN WORDS
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core techno…

NTLA −0.8% todayRead at source ↗
● Defense WorldOct 21, 2026 · 04:15 ET
Intellia Therapeutics (NASDAQ:NTLA) and Neurogene (NASDAQ:NGNE) Critical Survey

Intellia Therapeutics (NASDAQ: NTLA - Get Free Report) and Neurogene (NASDAQ: NGNE - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses bas…

NTLA −0.8% todayRead at source ↗
● Zacks Investment ResearchOct 20, 2026 · 11:30 ETEARNINGS EXPECTED BY JAN 22
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now

BBIO, NTLA, BIIB and VKTX offer investors potential upside from promising drug pipelines and upcoming FDA decisions and pivotal study results.…

NTLA −0.8% todayRead at source ↗
● GlobeNewsWireOct 13, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Intellia Therapeutics Appoints Jing L. Marantz, M.D.

CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core techno…

NTLA −0.8% todayRead at source ↗
● Defense WorldOct 12, 2026 · 01:58 ETEARNINGS EXPECTED BY JAN 22
Contrasting United Therapeutics (NASDAQ:UTHR) & Intellia Therapeutics (NASDAQ:NTLA)

Intellia Therapeutics (NASDAQ: NTLA - Get Free Report) and United Therapeutics (NASDAQ: UTHR - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on …

NTLA −0.8% todayRead at source ↗
● Zacks Investment ResearchOct 9, 2026 · 08:56 ETEARNINGS EXPECTED BY JAN 22
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?

Intellia Therapeutics (NTLA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.…

NTLA −0.8% todayRead at source ↗
● Defense WorldOct 8, 2026 · 07:41 ET
Intellia Therapeutics (NASDAQ:NTLA) Stock Picked Up by Analysts at Barclays

Barclays assumed coverage on shares of Intellia Therapeutics (NASDAQ: NTLA - Get Free Report) in a research report issued on Tuesday, MarketBeat.com reports. The brokerage set an "underweight" rating and a $8.00 price ta…

NTLA −0.8% todayRead at source ↗
● GlobeNewsWireOct 2, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core techno…

NTLA −0.8% todayRead at source ↗
● Defense WorldSep 21, 2026 · 02:16 ET
Financial Review: Intellia Therapeutics (NASDAQ:NTLA) vs. Bicycle Therapeutics (NASDAQ:BCYC)

Bicycle Therapeutics (NASDAQ: BCYC - Get Free Report) and Intellia Therapeutics (NASDAQ: NTLA - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two bus…

NTLA −0.8% todayRead at source ↗
● MarketBeatSep 19, 2026 · 00:02 ET
Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances

Intellia Therapeutics NASDAQ: NTLA executives outlined plans for a potential launch of its hereditary angioedema treatment, lonvo-z, while discussing the company's ongoing Phase III program in transthyretin amyloidosis a…

NTLA −0.8% todayRead at source ↗
● Zacks Investment ResearchSep 18, 2026 · 10:46 ET
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?

NTLA wins FDA priority review for lonvo-z, with a March 10, 2027 decision, potentially adding its first product, while nex-z studies are progressing well.…

NTLA −0.8% todayRead at source ↗
● Defense WorldSep 17, 2026 · 03:24 ET
Intellia Therapeutics (NASDAQ:NTLA) Stock Crosses Below Fifty Day Moving Average – What’s Next?

Intellia Therapeutics, Inc. (NASDAQ: NTLA - Get Free Report) shares passed below its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $12.10 and traded as low as $11.37. I…

NTLA −0.8% todayRead at source ↗
● Seeking AlphaSep 14, 2026 · 18:41 ET
Intellia Therapeutics, Inc. (NTLA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Intellia Therapeutics, Inc. (NTLA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

NTLA −0.8% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Jan 22. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just NTLA · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.